Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery

Mindset Pharma Inc

Mindset Pharma CEO James Lanthier joins Proactive's Natalie Stoberman to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery. Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state-of-the-art medicinal chemistry and behavioural pharmacology techniques to novel scaffolds of psychedelic drugs with the goal of discovering new medicines. He adds that the company has been working towards discovering novel psychedelic-inspired non-hallucinogenic drug candidates and has found multiple candidates with a promising preclinical profile. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

March 31, 2023 12:36 PM Eastern Daylight Time

Video

News Release

Todos Medical's Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing

Todos Medical Ltd.

Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista Diagnostics to license PCR-based sepsis diagnostic test AcuSept LDT rights From Acumen Diagnostics. Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

March 31, 2023 12:32 PM Eastern Daylight Time

Video

COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All

NanoViricides, Inc.

By David Willey, Benzinga Learn more about NanoViricides, Inc. by gaining access to the latest research report Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many times more deadly than influenza. A pan-coronavirus drug that is safe enough to be used by anyone and is highly effective remains an unmet medical need. NanoViricides Inc. (NYSEAMERICAN: NNVC), a leading biopharmaceutical company developing nanotechnology-based antiviral therapeutics, has been working on a pan-coronavirus antiviral to fulfill this unmet medical need. The company has been a drug discovery company for many years while it has looked to perfect its patented nanoviricide technology, a platform technology that deploys a novel mechanism to combat viruses. With this unique technology, the Company has reported developing a strong R&D pipeline of many antiviral drugs. NanoViricides is now excited to be transitioning into becoming a clinical-stage pharmaceutical company, and with a drug against COVID. The clinical trials of NV-CoV-2, the Company’s pan-coronavirus drug, are now imminent. The drug has already successfully completed the preclinical safety and effectiveness studies, and the Company has already set up cGMP manufacturing for the clinical drug products. NanoViricides Drug To Work Against All Current and Future COVID Variants? NV-CoV-2 is a broad-spectrum antiviral that looks to treat most human coronaviruses and will maintain its effectiveness as the variants mutate. This may mark a major step in the fight to find a permanent solution to COVID. Developing a drug that works against multiple COVID variants is key because as each variant mutates and spreads it has the risk of further widespread outbreaks causing an endemic or even a future pandemic. Despite the rollout of the vaccine from companies including Novavax Inc. (NASDAQ: NVAX), Moderna Inc. (NASDAQ: MRNA), AstraZeneca (NASDAQ: AZN), and Pfizer Inc. (NYSE: PFE), there are still over 170,000 infections weekly, as well as close to 3,000 hospitalizations and 1,800 deaths in the USA alone. COVID is still the biggest viral public health threat today. In the ongoing fight against the virus, one major battle is of coping with the multiple coronaviruses and the continuous evolution of their variants. In addition to SARS-CoV-2 and its variants, there are already four known seasonal human coronaviruses, hCoV-229E, hCoV-OC43, hCoV-HKU1, and hCoV-NL63, with NL63 causing the most similar symptoms to SARS-CoV-2. Any of these can lead to a more pathogenic variant in the near future. As these viruses continue to mutate, they render antibodies developed against previous strains ineffective. This means even so-called “ hybrid immunity ”– natural protection combined with vaccination – often only lasts for around eight months. It is important to note that all of the antibody drugs that were given emergency use authorizations (EUAs) have had the EUAs revoked upon becoming ineffective. NV-CoV-2 was found to work against many unrelated coronaviruses. So variants of SARS-CoV-2 (that causes COVID) are highly unlikely to be able to escape it. NanoViricides Drug NV-CoV-2 Could Cater To The Needs of All Patients Antiviral medication is an important way of coping with viral infections, other than vaccines and antibodies, as we all know from HIV. These drugs help the body fight off infection at the cellular level. However, there are significant issues with the antivirals currently on the market for treating COVID. These include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD), which either have limited effectiveness in treating the disease or carry the risk of serious side effects or both. Of note, they all have significant limitations on which category of patients can be helped. Unlike the existing COVID drugs, NanoViricides’ drug NV-CoV-2 caters to the needs of all patients. The Company has developed oral syrup and oral gummies for use in mild to moderate disease (out-patients). It has developed an injectable solution that can be injected, inhaled or infused, for use in severely ill or hospitalized patients. Having these multiple formulations gives the drug a broad range of applications; it would be available to patients with or without comorbidities and patients of all ages from a child to an octa(+)genarian. This unmatched useability is driven by its demonstrated strong safety and effectiveness in preclinical studies. The company also has the ability to manufacture clinical quantities of the drug products for clinical trials in its own “current Good Manufacturing Practices (cGMP)”-compliant facility, enabling time and cost savings. NanoViricides At An Inflection Point In Its Lifecycle? The company’s clinical trials could be ground-breaking — a novel anti-coronavirus drug, and the possibility for the trials to also prove that the Company’s platform is indeed capable of delivering clinical drugs. There is a whole pipeline of preclinical drugs that the Company intends to advance further. The global antiviral market was worth $48.1 billion in 2018 and is expected to grow to $79.8 billion at a compound annual growth rate (CAGR) of 6.7% from 2019 to 2026. Want to learn more about NanoViricides, Inc.? Visit its website. This article was originally published on Benzinga here. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

March 31, 2023 11:15 AM Eastern Daylight Time

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion

BioRestorative Therapies, Inc.

By Julian Richard, Benzinga BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome with another patent notice of allowance from the United States Patent Office, adding to its already 19 issued patents under the ThermoStem® patent family. BioRestorative’s ThermoStem® program is a novel cell-based therapy program using cells that have metabolic activity, that once transplanted may be able to regulate the bodies metabolic homeostasis (balance) and potentially induce weight loss and a better metabolic state. Metabolic syndrome is a cluster of conditions, such as obesity often times resulting in elevated cholesterol (fat) and glucose levels in the blood, these conditions increase the risk of developing type 2 diabetes, heart disease and stroke. Pioneering research conducted by Biorestorative Therapies demonstrated that brown tissue burns rather than stores energy. This work was published in Stem cells and was performed in a collaboration with the University of Utah. Increased levels of brown tissue support weight loss by increasing metabolism and reducing glucose and cholesterol in the blood. Thus, increasing brown fat levels and activity may be a powerful way to treat metabolic syndrome's significant mortality and morbidity. The ThermoStem® program is unique in that it pioneers the use of cell-based therapy to treat a global unmet medical need. The obesity and metabolic syndrome management space is the subject of intense clinical development and interest in the medical community. ThermoStem® will provide physicians with a therapeutic alternative to drugs with a different mechanism of action currently on the market. with Altimmune (NASDAQ: ALT), Eli Lilly Co (NYSE: LLY) and Pfizer Inc (NYSE: PFE) looking to emulate the success of Semaglutide, marketed by Novo Nordisk A/S (NYSE: NVO) for the treatment of obesity and type 2 diabetes. Semaglutide was FDA-approved in 2021 for “chronic weight management” and was the first drug approved for this indication since 2014. Because ThermoStem® is a biologic rather than a synthetic drug, it might be a safer alternative to drugs currently under development that have demonstrated safety issues, such as Altimmunes (NASDAQ: ALT) weight loss drug that demonstrated gastrointestinal side effects when used. Obesity: A Global Epidemic Type 1 and type 2 diabetes are two distinct forms of the same disease. Type 1 is an autoimmune disease, whereas type 2 is linked to lifestyle factors such as poor diet and lack of exercise resulting in obesity. Type 2 diabetes is caused by excess weight, poor diet and lack of exercise, leading to too much glucose (sugar) in the bloodstream. Cells in the body cannot respond as they would normally by removing glucose from the blood, a condition called insulin resistance. Type 2 diabetes can often be managed through diet and lifestyle changes such as eating a balanced diet, exercising regularly and maintaining a healthy weight. However, some people with type 2 diabetes may also need medication or insulin injections to manage their condition. Regardless of the type of diabetes, increased blood sugar can cause diseases of the heart, eyes and kidneys and may result in infection and amputation of the feet. The health economic burden of obesity and type 2 diabetes is profound. According to the Centers for Disease Control and Prevention (CDC), over 37 million Americans have diabetes (about 1 in 10), with up to 95% having type 2 diabetes. Type 2 diabetes has historically been considered a disease of adults; however, given the current obesity epidemic, it is becoming more common in children, adolescents and younger adults. By 2030, over one billion individuals will be obese, with 1 in 7 men and 1 in 5 women living with the condition. The World Health Organization has designated obesity as a global epidemic. The total annual cost of diabetes in the United States exceeds $327 billion. This includes direct medical costs, such as hospitalizations and medications, and indirect costs, from lost productivity due to illness or premature death. The burden of obesity and type 2 diabetes is not limited to economic factors alone. The impact of these conditions on the quality of life for patients and carers can be immense. People living with obesity and diabetes are at greater risk for physical, mental, social and emotional difficulties stemming from their condition. Mental health disorders such as anxiety and depression are common among people living with these conditions, partly due to the discrimination they can experience. Physical disability is also an issue for many people living with these conditions. The emotional toll of living with a chronic illness can be immense, leading to feelings of isolation, fear and frustration. ThermoStem® could potentially help with this burden through its novel approach. The novelty of the ThermoStem® technology was acknowledged by the United States Patent Office’s The Notice of Allowance was issued on February 24th of 2023. By expanding the ThermoStem® patent family with another issued patent, BioRestorative is positioned to further strengthen and secure its novel cell-based approach to treat obesity Visit https://www.biorestorative.com for more information on the company and its product candidates. This article was originally published on Benzinga. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

March 31, 2023 08:30 AM Eastern Daylight Time

Monogram Makes History with Fully Remote Simulated Robotic Surgery

Monogram Orthopedics

Monogram Orthopaedics Inc. is pleased to announce the successful completion of the first fully remote simulated robotic surgery in orthopedic history. On Tuesday, March 7th, 2023, at 2 PM Eastern, Douglas Unis, MD of the Icahn School of Medicine at Mount Sinai in New York City, successfully completed the world's first fully remote total knee arthroplasty (TKA) procedure on a cadaver, controlling the Austin-based robot from New York City in real-time via the systems user-operated foot pedal. The event was live telecast. “This was an incredible achievement for orthopedic robotics and medicine,” said founder Dr. Unis. “Despite being over 1,700 miles away, the real-time system was highly responsive with minimal latency. The applications for a robust system with these capabilities are tremendous. No system on the market today is capable of doing what Monogram just demonstrated.” With the help of state-of-the-art robotic technology, the navigated mBôs prototype has demonstrated the possibilities for the next generation of surgical robotics. A replay of the event is available here. “Our mission is to advance the standard of care in surgical robotics and orthopedics, “ said Ben Sexson, CEO. “I think we demonstrated that today with this historical demo. The achievement is a testament to our team's remarkable dedication and commitment.” Monogram recently announced it had initiated its final financing round as a private company before its planned listing on Nasdaq. Investors can purchase directly on the Company’s website. The company has applied to list its shares on Nasdaq. Once approved, Monogram will trade under the ticker symbol "MGRM." For more information on how to purchase shares, visit www.monogramorthopedics.com. About Monogram Orthopaedics Inc. Monogram Orthopaedics is a medical technology company commercializing robotics and implants for the orthopedic market. The Company is based in Austin, Texas. Monogram Orthopedics is changing the way orthopedic surgery is done. Our system combines personalized knee implants with precision robotic surgical assistants, giving patients a better-fitting knee replacement with minimally invasive surgery. 100,000 knee replacements failing each year in a $19.4B market represents an enormous opportunity for us. This release may include ‘’forward-looking statements.‘’ To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Monogram Orthopedics Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’Although Monogram Orthopedics Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Monogram Orthopedics Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Monogram are highly speculative. Investing in shares of Monogram involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.Monogram intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Monogram, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page. Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular. Contact Details Monogram Orthopaedics Loreana David +1 512-790-5151 info@monogramorthopedics.com

March 30, 2023 04:24 PM Eastern Daylight Time

OMID Posts 2022 Annual Report and Provides Update

Omid Hldgs Inc

McapMediaWire -- Today, OMID Holdings, Inc. (OTC: OMID ) posted its Unaudited Annual Report for the Year Ended December 31 st, 2022. The company is pleased to announce that its production facility in Alpha, NJ is now GMP-certified for the production of tinctures as human food according to FDA 21 CFR Part 117. "GMP certification has long been a stated goal of OMID and reaching this milestone has invigorated the OMID team. We believe that GMP certification represents a higher standard of operations within the cannabis industry and we intend to leverage our proven capabilities to take advantage of new business opportunities. As an additional note in response to broad shareholder inquiries: I would like to confirm that the financial audit is on-going with unwavering internal support and I am eager to see it completed." stated Adam Frank, Chairman & CEO of OMID Holdings, Inc. About OMID Holdings, Inc. OMID Holdings, Inc. is a publicly-traded health and wellness company which produces a variety of finished consumer goods. The company operates a facility in Alpha, NJ which is GMP-certified in the production of human food according to FDA 21 CFR Part 117. OMID concentrates its efforts on research, design, development, production, and marketing. Most of the products manufactured by the company include cannabinoids derived from hemp and other herbal ingredients. Acts 2:12 For more information about the company, please visit https://omidholdingsinc.com/ or follow us on Twitter: @OMIDHoldingsInc Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Adam Frank Phone: +1 908-386-2880 Email: info@omidholdingsinc.com Contact Details OMID Holdings, Inc. info@omidholdingsinc.com Company Website https://omidholdingsinc.com/

March 30, 2023 09:15 AM Eastern Daylight Time

Premier Biomedical Inc. (OTC: BIEI), Welcomes Officers, Directors and Key Advisors

Premier Biomedical Inc

McapMediaWire -- Premier Biomedical Inc., now known as Premier Graphene, Inc. (OTC: BIEI ), has relocated its headquarters to Imperial Valley, CA. CEO Ivan Mendez welcomes its new officers, directors, and other significant participants. As Vice President, Noe Gallego will spearhead our Mexico hemp procurement operations. Mr. Gallego shared the following, “I am excited to be at the forefront of a rapidly growing industry, with a talented group of persons involved in Premier Graphene, Inc. (Premier). Premier is uniquely poised to revolutionize a variety of industrial sectors from health and wellness to aerospace and construction. With the aid of its counsel in Mexico, Premier Graphene Inc will permit low-cost and robust growing operations to supply high-quality hemp as the principal raw material component for producing the highest-quality graphene that is eco-friendly. Perhaps ironically, it will also inevitably be at a more accessible cost. Indeed, it will be particularly well-suited for Premier’s wide range of products. Perhaps equally important, the environment in Mexico permits 3 Growth cycles per year for this type of industrial hemp, which is the highest quality and best-suited for high-grade graphene production.” Chief of Legal Operations in Mexico and Latin America, Ana Erika Santana, Esq., presently is assisting the federal government of Mexico to codify cannabis and hemp laws and to enact appropriate regulations consistent with such initiatives. Ms. Santana specializes in compliance within both the corporate and government sectors. Ms. Santana added, “To have a successful business, we must have full compliance and cooperation among governmental bodies. I will also ensure conformity with social responsibility which is particularly important within this sector. My strong connections with the Mexican government prompt my participation with Premier Graphene and create my optimism for its future.” Dr. George Stantchev, will serve as a scientific consultant to Premier. Dr. Stantchev is the owner of four European companies that have a presence in North America. The first company, AEMC Technologies, is principally focused on thermal night vision units for military and commercial use. It also engages in product and business management consulting for medical imaging, defense imaging, consumer, automotive, industrial computing, and wireless communications. Next is COMERG. It employs top-notch engineering for the development of medicinal grade extracts and AG technology specialized equipment and machinery. Dr. Stantchev is also the founder of DIAMAGNETIX, a tech innovation company, specializing in improving key processes in the development of Bio and Energy in a nano-material state. His last company, Pure 5 Extractions Systems, is a leading innovative botanical extraction company, with a specific focus on hemp and cannabis. Dr. Stantchev has worked on product development and manufacturing projects with Fortune 500 companies. Ivan Mendez added that “I have had the great pleasure of knowing and working with George for 5 years, in the Cannabis medicinal use field, George will be able to help us with Worldwide resource allocation and client-oriented multi-country product development and manufacturing. I find him to be a great scientist and a leader in the cannabis and hemp extraction business worldwide. He has a brilliant mind and is willing to help when he can.” Dr. Richard Goulding, Chief Medical Officer, will be pursuing the development of medical applications for graphene. This includes unique and extremely efficacious applications for medical instrumentation. Dr. Goulding stated that “my colleagues will be assisting me in developing applications for medical research and development utilizing the unique prospect of graphene involved in fluid filtration processes.” CFO and Human Resources officer, Yvonne Gallego stated, “I am excited about the potential of this rapidly growing industry and the opportunities it lends to financial growth, quality products, and innovation. I am enthusiastic about leading a business that promotes sustainability and environmental stewardship through the cultivation and use of this versatile crop to be employed in our graphene production.” “I believe Mrs. Gallego will be a valuable asset to our company just as she was at HGI Pharma Inc.” states CEO Ivan Mendez. Josh Rockwell, VP of Pulp and Paper Division. “I am excited to join Premier Graphene Inc. as VP of the Pulp and Paper Division. I am a chemical engineer from the University of New Hampshire with 25 years of innovating in the pulp and paper industry through continuous improvement. Hemp will revolutionize the way paper and other vital materials are made. I am proud to join this talented team”. “I am confident Josh’s role in Premier Graphene Inc. His vast experience will prove invaluable to our path forward” added CEO Ivan Mendez. Chief Operating Officer, Mark Kingston, will oversee the day-to-day operations and some of the product development. He will interface with Biographene Technology, 10% owned by Premier, to assure a sufficient quantity of high-grade graphene manufacturing. Mr. Kingston added, “As the Chief Operating Officer of US Hemp Hurd and founder of Pyrotech US Inc., I bring a wealth of experience in managing and minimizing operational risks, ensuring regulatory compliance, and building relationships with stakeholders, customers, suppliers, and partners”. Leveraging his industrial engineering background, Mr. Kingston will drive key innovation and enhance efficiency to ensure that Premier remains at the forefront of R&D, market awareness, and delivery of commercial products and systems. “We are confident that Mark's contributions will play a crucial role in the success of our organization,” says senior consultant Pedro “Pete” Mendez. Pedro “Pete” Mendez, senior consultant to the Board, industrial hemp and cannabis researcher, and entrepreneur, specializing in acquisitions and cannabis products. As a former project manager for HGI Pharma Inc., Mr. Mendez stated: “I believe we will become the dominant force in quality graphene production (for all uses) in North America. We have assembled a unique team. We are fostering innovative technology, manufacturing, and creating a new supply chain that we can control, we will be disrupting the mined graphite market”. CEO Ivan Mendez states: “We are still in the process of interviewing two candidates for Chief Technology officer. We will be providing that information and some very exciting updates as they occur. See below links concerning the above-identified persons and associated entities: http://www.aemctech.com www.Irarm.com http://www.pure5extraction.com/ http://www.comerg.com https://www.linkedin.com/in/stantchev https://www.linkedin.com/in/yvonne-mendez-gallego-psy-m-bsb-8747a812 https://www.linkedin.com/in/erikasantanaabogada https://www.linkedin.com/in/joshuaarockwell https://www.linkedin.com/in/ushemphurd https://ushemphurd.com/ https://uspyrolyzer.com/ https://www.linkedin.com/in/pedro-mendez-a504741ba To get the latest news on the exciting developments from Premier Biomedical Inc. (OTC: BIEI), now known as Premier Graphene, Inc., subscribe by submitting to: https://premiergrapheneinc.com/contact/ For more information, please contact us at: info@premiergrapheneinc.com Website (work in process): https://premiergrapheneinc.com Twitter: @PremierBiomedic https://twitter.com/PremierBiomedic About Premier Graphene, Inc. (OTC: BIEI ), engaged in a holding company reorganization so that the parent company, renamed from “Premier Biomedical Inc.”, has almost no convertible debentures (less than $20,000) outstanding. As a result, the successor issuer public company, Premier Graphene, Inc., has nearly no debt. The predecessor issuer’s debt remains in the original company, now a subsidiary of the publicly traded company. The Company is traded on the OTC Market, in full compliance with OTC Market reporting requirements. Premier Graphene, Inc. is in the process of a single corporate action – changing its name with FINRA and thus OTC Markets. Its articles of incorporation prohibit a reverse split. It is involved in the development of sophisticated products utilizing the unique characteristics of graphene, partnering with various related corporations and unrelated corporations. Safe Harbor Notice Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Premier Graphene, Inc. (OTC: BIEI ), whose name is being changed from Premier Biomedical Inc., undertakes no obligation to revise these statements following the date of this news release. Contact Details Premier Graphene, Inc. info@premiergrapheneinc.com

March 30, 2023 09:00 AM Eastern Daylight Time

Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment

Odyssey Group Intl Inc.

McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY ), f/k/a Odyssey Group International, Inc., a company focused on creating unique, life-enhancing medical products, is developing a novel neuropharmaceutical treatment for mild Traumatic Brain Injury (mTBI) also known as a concussion. Recently, the world’s leading research agency, the National Institutes of Health (NIH), acknowledged that Chronic Traumatic Encephalopathy (CTE) is caused by repetitive head trauma, not uncommon in the field of sports and in our military. Odyssey’s lead drug candidate, ONP-002, is designed for the acute setting using an intranasal neurosteroid that works to simultaneously reduce swelling, inflammation, and oxidative stress. Odyssey has completed a Phase I clinical trial and is now preparing for a Phase II study to determine the safety and efficacy of its drug. The National Football League (NFL) announced an eighteen percent (18%) increase in concussions sustained in the 2022 season compared to 2021, potentially due to the increased sideline concussion protocols. On average the NFL conducts 1.6 sideline concussion evaluations per game. Data from a recently completed study showed that older retired NFL players had an increased rate of neurocognitive decline compared to non-players. Interestingly, a history of concussion where consciousness was lost had the greatest effect on neurocognitive performance in older athletes. The NFL and NCAA continue to deal with legal claims surrounding concussions. Internationally, Australian Rules footballers have recently brought legal action against the league for downplaying the risk of head injury and failing to have proper protocols in place to protect the players. The cost to the league could be as high as $2 million per player. The league recently reversed its stance and now accepts that CTE is caused in part by repetitive head trauma. In the past few years, concussions in elite rugby leagues have hit an all-time high since records kept. Over twenty-two (22) concussions were documented per one thousand (1000) hours of rugby play. In a significant move, the leagues have instituted a 12-day no-play clause if the player is diagnosed with a concussion. “Given the reported incidences cited, Odyssey Health recognizes the urgent need to bring an effective pharmaceutical to market to treat the concussion epidemic. Not only are the therapeutic effects of the drug vital, but there is a need for a field-deliverable and brain-targeted approach to the drug delivery. Our intranasal delivery should optimize the success of the drug when given to our athletes,” commented Michael Redmond, CEO for Odyssey Health, Inc. About Odyssey Health Inc. (formerly Odyssey Group International, Inc.) Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus on life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the Company’s website at www.odysseyhealthinc.com We encourage our shareholders to visit our corporate social media accounts for updates: https://twitter.com/OdysseyHealth1 https://www.facebook.com/odysseyhealthinc https://www.linkedin.com/company/odysseyhealthinc https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q About ONP-002 ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, ONP-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that ONP-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, ONP-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Our novel breath-propelled, intranasal brain-drug delivery device is designed with a novel drug dispensing system that creates an effective airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region, this could allow for quick and direct diffusion into the brain.. Forward-Looking Statements This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete clinical trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions. Inquiries: Odyssey Health info@odysseyhealthinc.com Contact Details Odyssey Health info@odysseyhealthinc.com

March 30, 2023 08:30 AM Eastern Daylight Time

BiVictriX Therapeutics to "continue seeking out positive relationships"

BiVictriX Therapeutics PLC

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) founder and CEO Tiffany Thorn speaks to Proactive after releasing full year results for 2022, a year that she describes as "very good" for the UK-based drug discovery and development company. Thorn reveals what she was most pleased with from the year before turning her focus to her priorities for 2023, highlighting a desire to grow the company's profile and to "continue seeking out positive relationships." Here's more on that story: BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) has said it is focused on three value creation points for its lead asset BVX001, which is being developed to treat acute myeloid leukaemia. In working towards these goals it believes it will attract the attention of potential partners for what could eventually be a blockbuster treatment. It also reckons this work will provide validation for its Bi-Cygni platform, which aims to develop targeted cancer drugs with fewer side effects. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 30, 2023 05:20 AM Eastern Daylight Time

Video

1 ... 120 121 122 123 124 ... 282